Implantable cardioverter defibrillator therapy for primary prevention of sudden cardiac death in the real world: Main findings from the French multicentre DAI-PP programme (pilot phase).
Complications
Défibrillateur automatique implantable
Epidemiology
Implantable cardioverter defibrillator
Mort subite cardiaque
Primary prevention
Prévention primaire
Sudden cardiac death
Épidémiologie
Journal
Archives of cardiovascular diseases
ISSN: 1875-2128
Titre abrégé: Arch Cardiovasc Dis
Pays: Netherlands
ID NLM: 101465655
Informations de publication
Date de publication:
Historique:
received:
17
04
2019
accepted:
21
05
2019
pubmed:
1
9
2019
medline:
28
11
2019
entrez:
1
9
2019
Statut:
ppublish
Résumé
This review summarizes the main findings of the French multicentre DAI-PP pilot programme, and discusses the related clinical and research perspectives. This project included retrospectively (2002-2012 period) more than 5000 subjects with structural heart disease who received an implantable cardioverter defibrillator (ICD) for primary prevention of sudden cardiac death, and were followed for a mean period of 3 years. The pilot phase of the DAI-PP programme has provided valuable information on several practical and clinically relevant aspects of primary prevention ICD implantation in the real-world population, which are summarized in this review. This pilot has led to a prospective evaluation that started in May 2018, assessing ICD therapy in primary and secondary prevention in patients with structural and electrical heart diseases, with remote monitoring follow-up using a dedicated platform. This should further enhance our understanding of sudden cardiac death, to eventually optimize the field of preventative actions.
Identifiants
pubmed: 31471226
pii: S1875-2136(19)30128-7
doi: 10.1016/j.acvd.2019.05.005
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
523-531Informations de copyright
Copyright © 2019 Elsevier Masson SAS. All rights reserved.